Varian Executive and Leadership Team

Jiahong Li, the Director, Finance & Chief Financial Officer (APAC) at Varian, manages all fiscal operations across the Asia-Pacific region. Overseeing regional capital allocation and budgetary planning, the Director, Finance & Chief Financial Officer (APAC) ensures alignment with corporate growth targets. This leadership role involves mitigating financial risks while supporting the expansion of medical device distribution networks. By optimizing regional revenue streams, Jiahong Li directly impacts the company's ability to scale radiotherapy and proton therapy access. Furthermore, the Director, Finance & Chief Financial Officer (APAC) collaborates with global leadership to maintain fiscal discipline. Through rigorous oversight of regional accounting practices, the executive secures long-term stability for the organization. This position remains vital for navigating complex regulatory environments and ensuring consistent investment in cancer treatment technologies throughout the APAC market.

Stephen Jamison, the President, Proton Solutions at Varian, directs the development and deployment of advanced proton therapy systems. Overseeing the engineering and commercialization of high-precision cancer treatment hardware, the President, Proton Solutions ensures technological superiority in the global market. This leadership role involves coordinating with clinical partners to refine proton therapy delivery methods. By driving innovation in particle therapy, Stephen Jamison directly impacts the company's mission to provide precise, non-invasive treatment options. Furthermore, the President, Proton Solutions manages the integration of software platforms that enhance treatment planning efficiency. Through strategic oversight of global installations, the executive expands the reach of proton therapy to major medical centers. This position remains essential for maintaining the company's competitive edge in the specialized field of radiotherapy and ensuring that clinical teams possess the most effective tools for patient care.

Sasa Mutic, the President, Radiation Oncology Solutions at Varian, architects the strategic roadmap for the core radiotherapy business unit. Overseeing the product lifecycle of linear accelerators and treatment planning software, the President, Radiation Oncology Solutions ensures that clinical workflows remain efficient and patient-centric. This leadership role involves collaborating with research teams to integrate artificial intelligence into oncology software. By optimizing the performance of radiotherapy hardware, Sasa Mutic directly impacts the company's ability to deliver high-quality cancer care globally. Furthermore, the President, Radiation Oncology Solutions manages cross-functional teams to accelerate the adoption of adaptive therapy techniques. Through consistent focus on clinical outcomes, the executive drives the evolution of standard-of-care practices. This position remains critical for sustaining the company's market leadership and ensuring that oncology departments worldwide utilize the most advanced, reliable, and scalable treatment solutions available.

Andrew Shogan, the President, Multi-Disciplinary Oncology at Varian, manages the integration of comprehensive care solutions across various oncology specialties. Overseeing the development of software ecosystems that connect radiotherapy, surgery, and medical oncology, the President, Multi-Disciplinary Oncology ensures seamless data flow for clinical teams. This leadership role involves coordinating with hospital networks to implement holistic cancer care models. By driving the adoption of integrated software platforms, Andrew Shogan directly impacts the company's ability to support multi-disciplinary treatment planning. Furthermore, the President, Multi-Disciplinary Oncology manages the strategic expansion of digital health tools that enhance collaboration among oncologists. Through consistent focus on patient-centered care, the executive improves the efficiency of complex treatment pathways. This position remains critical for transforming the company into a provider of end-to-end oncology solutions and ensuring that healthcare providers can deliver coordinated, high-quality care to patients facing diverse medical conditions.

David Hahn, the Varian Interventional Solutions Vice President & Chief Medical Officer at Varian, leads the clinical strategy for interventional oncology products. Overseeing the development of minimally invasive devices, the Varian Interventional Solutions Vice President & Chief Medical Officer ensures that product design aligns with current clinical needs. This leadership role involves bridging the gap between engineering teams and practicing physicians to refine procedural tools. By advancing interventional techniques, David Hahn directly impacts the company's portfolio of brachytherapy and embolization solutions. Furthermore, the Varian Interventional Solutions Vice President & Chief Medical Officer provides medical guidance to ensure safety and efficacy across all interventional product lines. Through strategic engagement with the medical community, the executive fosters innovation in image-guided procedures. This position remains vital for expanding the company's footprint in the interventional space and improving patient recovery times through precise, technology-driven medical interventions.

Dee Khuntia, the Senior Vice President, Medical Affairs & Chief Medical Officer at Varian, directs the global clinical evidence and medical safety programs. Overseeing the scientific validation of radiotherapy and software solutions, the Senior Vice President, Medical Affairs & Chief Medical Officer ensures that all products meet rigorous clinical standards. This leadership role involves managing relationships with global health authorities and academic institutions to promote evidence-based oncology practices. By championing clinical research, Dee Khuntia directly impacts the company's reputation for excellence in cancer treatment. Furthermore, the Senior Vice President, Medical Affairs & Chief Medical Officer provides medical oversight for product development, ensuring that patient safety remains the primary focus. Through strategic leadership in medical affairs, the executive guides the organization toward future clinical breakthroughs. This position remains essential for maintaining trust with the medical community and ensuring that all technological advancements translate into improved patient survival rates.